Abstract:Background and Purpose Metabotropic glutamate receptor 1 (mGlu1) is a promising therapeutic target for neurodegenerative CNS disorders including spinocerebellar ataxias (SCAs). Clinical reports have identified naturally‐occurring mGlu1 mutations in rare SCA subtypes and linked symptoms to mGlu1 mutations. However, how mutations alter mGlu1 function remains unknown, as does amenability of receptor function to pharmacological rescue. Here, we explored SCA‐associated mutation effects on mGlu1 cell surface expression, canonical signal transduction and allosteric ligand pharmacology. Experimental Approach Orthosteric agonists, positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) were assessed at two functional endpoints (iCa2+ mobilisation and inositol 1‐phosphate [IP1] accumulation) in FlpIn Trex HEK293A cell lines expressing five mutant mGlu1 subtypes. Key pharmacological parameters including ligand potency, affinity and cooperativity were derived using operational models of agonism and allostery. Key Results mGlu1 mutants exhibited differential impacts on mGlu1 expression, with a C‐terminus truncation significantly reducing surface expression. Mutations differentially influenced orthosteric ligand affinity, efficacy and functional cooperativity between allosteric and orthosteric ligands. Loss‐of‐function mutations L454F and N885del reduced orthosteric affinity and efficacy, respectively. A gain‐of‐function Y792C mutant mGlu1 displayed enhanced constitutive activity in IP1 assays, which manifested as reduced orthosteric agonist activity. The mGlu1 PAMs restored glutamate potency in iCa2+ mobilisation for loss‐of‐function mutations and mGlu1 NAMs displayed enhanced inverse agonist activity at Y792C relative to wild‐type mGlu1. Conclusion and Implications Collectively, these data highlight distinct mechanisms by which mGlu1 mutations affect receptor function and show allosteric modulators may present a therapeutic strategy to restore aberrant mGlu1 function in rare SCA subtypes.

Glutamate acts as a partial inverse agonist to metabotropic glutamate receptor with a single amino acid mutation in the transmembrane domain

Structural Basis of Orientated Asymmetry in a Mglu Heterodimer

Molecular Recognition of Metabotropic Glutamate Receptor Type 1 (mglur1): Synergistic Understanding with Free Energy Perturbation and Linear Response Modeling

Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization

Structural insights into the activation of metabotropic glutamate receptors

Heptahelical Domain of Metabotropic Glutamate Receptor 5 Behaves Like Rhodopsin-Like Receptors

G-protein activation by a metabotropic glutamate receptor

Constitutive activity of ionotropic glutamate receptors via hydrophobic substitutions in the ligand-binding domain

Investigation of Allosteric Modulation Mechanism of Metabotropic Glutamate Receptor 1 by Molecular Dynamics Simulations, Free Energy and Weak Interaction Analysis

Exploring the Activation Mechanism of a Metabotropic Glutamate Receptor Homodimer Via Molecular Dynamics Simulation.

Elucidating the molecular logic of a metabotropic glutamate receptor heterodimer

Exploring the Activation Mechanism of Metabotropic Glutamate Receptor 2

Concerted Conformational Changes Control Metabotropic Glutamate Receptor Activity.

Structural basis of positive allosteric modulation of metabotropic glutamate receptor activation and internalization

Agonist-independent Activation of Metabotropic Glutamate Receptors by the Intracellular Protein Homer

SCA44‐ and SCAR13‐associated GRM1 mutations affect metabotropic glutamate receptor 1 function through distinct mechanisms

Signaling Specificity and Kinetics of the Human Metabotropic Glutamate Receptors

A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model.

Dissecting Conformational Rearrangements and Allosteric Modulation in Metabotropic Glutamate Receptor Activation

Different Functional Roles of Arginine Residues 39 and 61 and Tyrosine Residue 98 in Transport and Channel Mode of the Glutamate Transporter EAAC1

Direct M3-M4 Interactions Control NMDA Receptor Gating and Desensitization